Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

BriaCell Invited to Present at Mount Sinai's Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

GlobeNewswire January 22, 2020

BriaCell Provides Update on Remarkable Responder

GlobeNewswire January 13, 2020

BriaCell Outlines New High Responding Patient Group 'Biomarker' Based on Cancer Grade

GlobeNewswire January 9, 2020

BriaCell Completes Share Consolidation

GlobeNewswire January 2, 2020

BriaCell Therapeutics Corp. Announces Share Consolidation

GlobeNewswire December 24, 2019

BriaCell to Present at Biotech Showcase(TM) 2020 in San Francisco

GlobeNewswire December 17, 2019

BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

GlobeNewswire December 13, 2019

BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

GlobeNewswire November 12, 2019

BriaCell Announces Voting Results of the Special Meeting of Shareholders

GlobeNewswire October 24, 2019

BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

GlobeNewswire October 15, 2019

BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

GlobeNewswire October 8, 2019

BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT(TM) in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

GlobeNewswire October 7, 2019

BriaCell Therapeutics Corp. to Clarify Record Date

GlobeNewswire October 1, 2019

Note from Chairman of BriaCell Therapeutics - October is Breast Cancer Awareness Month

GlobeNewswire October 1, 2019

BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

GlobeNewswire September 25, 2019

BriaCell Announces Private Placement of up to $600,000

GlobeNewswire September 20, 2019

IIROC Trading Resumption - BCT

Canada NewsWire September 19, 2019

BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

GlobeNewswire September 19, 2019

IIROC Trading Halt - BCT

Canada NewsWire September 19, 2019

BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

GlobeNewswire September 16, 2019